Experienced in Vaginal Bleeding Between Periods

Dr. Latoya J. Perry

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Beacon Medical Group Inc
100 Navarre Pl, 4470 Bmg Womens Surgical G, 
South Bend, IN 
Accepting New Patients
Experienced in Vaginal Bleeding Between Periods
Beacon Medical Group Inc
100 Navarre Pl, 4470 Bmg Womens Surgical G, 
South Bend, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Latoya Perry is a Gynecologic Oncologist and an Oncologist in South Bend, Indiana. Dr. Perry is rated as an Experienced provider by MediFind in the treatment of Vaginal Bleeding Between Periods. Her top areas of expertise are Vulvar Cancer, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Lymphadenectomy, and Bladder Reconstruction. Dr. Perry is currently accepting new patients.

Her clinical research consists of co-authoring 5 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Medical College Of Wisconsin
Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in IN
Hospital Affiliations
Pulaski Memorial Hospital
Elkhart General Hospital
Memorial Hospital Of South Bend
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

BEACON MEDICAL GROUP INC
100 Navarre Pl, 4470 Bmg Womens Surgical G, South Bend, IN 46601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug, Other
Study Drug: Copanlisib
Study Phase: Phase 2
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
Enrollment Status: Unknown
Publish Date: December 29, 2021
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: October 12, 2021
Intervention Type: Drug
Study Drug: Tivozanib
Study Phase: Phase 2
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Enrollment Status: Unknown
Publish Date: February 19, 2018
Intervention Type: Other, Behavioral
Study Phase: Phase 3
View 12 Less Clinical Trials

5 Total Publications

Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation.
Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 21, 2014
Similar Doctors
Matthew Tipton
Advanced in Vaginal Bleeding Between Periods
Dr. Matthew Tipton
Obstetrics and Gynecology
Advanced in Vaginal Bleeding Between Periods
Dr. Matthew Tipton
Obstetrics and Gynecology

NorthShore Health Centers

2200 Grant St, 
Gary, IN 
 (57.6 miles away)
219-763-8112
Languages Spoken:
English
See accepted insurances

Dr. Tipton is committed to the field of medicine to revitalize communities such as his hometown of Gary, IN. Through pathways laid out by role models, he was able to achieve his dream. His ultimate goal is to inspire young people in his community and demonstrate to them that anything is possible.Dr. Tipton’s family is deeply rooted in Northwest Indiana, including his life with his wife, Dr. Cydney Bullock-Tipton. He enjoys all types of activities with her. He is also a huge sports fan (Go Bulls/Bears/Sox!) and has a strong passion for hip-hop music. Dr. Tipton is rated as an Advanced provider by MediFind in the treatment of Vaginal Bleeding Between Periods. His top areas of expertise are Chlamydia, Vaginal Cysts, Vaginal Dryness, Trichomoniasis, and Intrauterine Device Insertion.

Advanced in Vaginal Bleeding Between Periods
Dr. Prinn K. Stang
Obstetrics and Gynecology
Advanced in Vaginal Bleeding Between Periods
Dr. Prinn K. Stang
Obstetrics and Gynecology
99 E 86th Ave B, 
Merrillville, IN 
 (57.7 miles away)
219-738-3220
Languages Spoken:
English, Thai
See accepted insurances

Prinn Stang is an Obstetrics and Gynecologist in Merrillville, Indiana. Dr. Stang is rated as an Advanced provider by MediFind in the treatment of Vaginal Bleeding Between Periods. His top areas of expertise are Endometriosis, Vaginal Bleeding Between Periods, Angiomyoma, and Uterine Fibroids.

Advanced in Vaginal Bleeding Between Periods
Dr. Ilana T. Kirsch
Obstetrics and Gynecology
Advanced in Vaginal Bleeding Between Periods
Dr. Ilana T. Kirsch
Obstetrics and Gynecology

Family Medicine Of South Bend PC

6301 University Commons, Suite 210, 
South Bend, IN 
 (3.8 miles away)
574-234-4016
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Ilana Kirsch is an Obstetrics and Gynecologist in South Bend, Indiana. Dr. Kirsch is rated as an Advanced provider by MediFind in the treatment of Vaginal Bleeding Between Periods. Her top areas of expertise are Vaginal Bleeding Between Periods, Menopause, Angiomyoma, Uterine Fibroids, and Intrauterine Device Insertion. Dr. Kirsch is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Perry's expertise for a condition
ConditionClose
      View All 12 Advanced Conditions
      View All 18 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile